A large pulmonary nodule in a rheumatoid arthritis patient treated with tofacitinib.

Int J Rheum Dis

Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.

Published: January 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Pulmonary rheumatoid nodules are rare extra-articular manifestations of rheumatoid arthritis (RA). They are usually asymptomatic but may form cavities and cause clinical symptoms. These nodules are difficult to differentiate clinically and radiologically from tuberculosis, fungal infection, or lung malignancies. Histopathological studies help in the differential diagnosis of pulmonary nodules in patients with RA; however, an effective treatment for rheumatoid lung nodules has not yet been established. This study reports a case of active RA with interstitial lung disease and a large inflammatory lung nodule that was improved with tofacitinib treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.15013DOI Listing

Publication Analysis

Top Keywords

rheumatoid arthritis
8
large pulmonary
4
pulmonary nodule
4
rheumatoid
4
nodule rheumatoid
4
arthritis patient
4
patient treated
4
treated tofacitinib
4
tofacitinib pulmonary
4
pulmonary rheumatoid
4

Similar Publications

IntroductionTo investigate the effectiveness of the remote video-based Strengthening and Stretching for Rheumatoid Arthritis of the Hand (SARAH) exercise program in individuals with rheumatoid arthritis (RA) with wrist involvement.MethodsSeventy-three individuals were included in the study. Wrist joint position sense, wrist joint range of motion, wrist pain, wrist morning stiffness, subjective and objective hand function, grip strength, and disease-related health status were assessed at baseline and after 12 weeks.

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which dysregulated interferon regulatory factor 5 (IRF5) may amplify pro-inflammatory pathways; prior genetic studies of IRF5 single-nucleotide variants (SNVs) in RA are inconsistent across populations and have not included mestizo Mexicans or evaluated rs59110799 in RA. We aimed to test whether four IRF5 SNVs (rs2004640G/T, rs2070197T/C, rs10954213G/A, rs59110799G/T) confer susceptibility to RA in women from Central Mexico. In a case-control study of 239 women with RA and 231 female controls (all self-identified Mexican-Mestizos, ≥3 generations), genotyping was performed by real-time PCR with TaqMan® probes; 80% of samples were duplicated (100% concordance) and control genotypes conformed to Hardy-Weinberg equilibrium.

View Article and Find Full Text PDF

Anti-inflammatory and immunomodulatory effect of purslane and turmeric in rheumatoid arthritis rat models.

Cell Mol Biol (Noisy-le-grand)

September 2025

Department of Chemistry, Faculty of Science and Health, Koya University, Koya, KOY45, Kurdistan Region, Iraq.

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation. Given the side effects of conventional treatments, this study focuses on the anti-inflammatory effects of purslane (Portulaca oleracea) and turmeric (Curcuma longa). The research is driven by the growing demand for plant based-treatment for safer therapeutic options for RA management.

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation and is often associated with poor oral health. Cytokines play a central role in RA immunopathogenesis. This case-control study investigated the involvement of salivary interleukin-17A (IL-17A) and interleukin-18 (IL-18) in RA patients in relation to oral health status.

View Article and Find Full Text PDF

The Impact of Obesity and Overweight on Rheumatoid Arthritis Patients: Real-World Insights from a Biologic and Targeted Synthetic DMARDs Registry. The management of rheumatoid arthritis (RA) has advanced with biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). However, obesity, a common comorbidity, impacts treatment and disease progression efficacy.

View Article and Find Full Text PDF